Trial Profile
A randomised, double-blind, placebo-controlled, parallel-group trial investigating the effect of 4 weeks bi-daily dosing of XEN-D0501 on blood glucose reduction as add-on to metformin in patients with diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs XEN D0501 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors PILA PHARMA
- 05 Jan 2020 Status changed from recruiting to completed.
- 15 Sep 2018 Status changed from planning to recruiting.
- 30 Aug 2017 New trial record